Login to Your Account

Seattle Genetics launches pivotal phase III for CD33-targeted ADC

By Michael Fitzhugh
Staff Writer

Wednesday, May 25, 2016

Seattle Genetics Inc. (Seagen) started its second-ever phase III study, pitting a CD33-targeted antibody-drug conjugate paired with widely used HMA vs. HMAs alone in older patients with newly diagnosed AML.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription